← Back to Screener
BioCryst Pharmaceuticals Inc (BCRX)
Price$9.52
Favorite Metrics
Price vs S&P 500 (26W)25.68%
Price vs S&P 500 (4W)-2.77%
Market Capitalization$2.38B
P/E Ratio (Annual)9.02x
All Metrics
P/CF (Annual)6.85x
Book Value / Share (Quarterly)$0.19
P/TBV (Annual)15.62x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)47.83%
Cash Flow / Share (Quarterly)$1.62
Price vs S&P 500 (YTD)18.38%
Gross Margin (TTM)97.82%
Net Profit Margin (TTM)30.16%
EPS (TTM)$1.20
10-Day Avg Trading Volume4.86M
EPS Excl Extra (TTM)$1.20
Revenue Growth (5Y)117.92%
EPS (Annual)$1.21
ROI (Annual)-92.13%
Gross Margin (Annual)97.82%
Net Profit Margin (5Y Avg)-53.26%
Cash / Share (Quarterly)$1.29
P/E Basic Excl Extra (TTM)9.02x
Revenue Growth QoQ (YoY)209.09%
P/E Normalized (Annual)9.02x
ROA (Last FY)51.32%
Revenue Growth TTM (YoY)94.10%
EBITD / Share (TTM)$1.54
ROE (5Y Avg)-820.53%
Operating Margin (TTM)37.00%
Cash Flow / Share (Annual)$1.62
P/B Ratio70.80x
P/B Ratio (Quarterly)18.05x
Net Income / Employee (Annual)$1
EV / Revenue (TTM)3.15x
Net Interest Coverage (TTM)4.91x
ROA (TTM)55.61%
EV / EBITDA (TTM)8.18x
EPS Incl Extra (Annual)$1.21
Current Ratio (Annual)2.06x
Quick Ratio (Quarterly)1.95x
3-Month Avg Trading Volume5.01M
52-Week Price Return34.09%
EV / Free Cash Flow (Annual)8.00x
P/E Incl Extra (TTM)9.02x
Revenue / Employee (TTM)$2
Tangible BV / Share (Quarterly)$1.73
P/S Ratio (Annual)2.72x
Asset Turnover (Annual)1.70x
52-Week High$11.31
Operating Margin (5Y Avg)-27.19%
EPS Excl Extra (Annual)$1.21
CapEx CAGR (5Y)37.07%
Tangible BV CAGR (5Y)-18.04%
26-Week Price Return29.67%
Quick Ratio (Annual)1.95x
13-Week Price Return33.15%
Total Debt / Equity (Annual)2.09x
Current Ratio (Quarterly)2.06x
Enterprise Value$2,757.549
Revenue / Share Growth (5Y)106.57%
Asset Turnover (TTM)1.84x
Book Value / Share Growth (5Y)-25.06%
Revenue / Employee (Annual)$2
Inventory Turnover (Annual)2.83x
Pretax Margin (Annual)30.56%
Cash / Share (Annual)$1.29
3-Month Return Std Dev53.06%
Gross Margin (5Y Avg)97.31%
Net Income / Employee (TTM)$1
ROE (Last FY)-284.33%
Net Interest Coverage (Annual)4.91x
EPS Basic Excl Extra (Annual)$1.21
P/FCF (TTM)6.39x
Receivables Turnover (TTM)9.41x
EV / Free Cash Flow (TTM)8.00x
Total Debt / Equity (Quarterly)2.26x
EPS Incl Extra (TTM)$1.20
Receivables Turnover (Annual)9.41x
ROI (TTM)-106.66%
P/S Ratio (TTM)2.72x
Pretax Margin (5Y Avg)-52.58%
Revenue / Share (Annual)$4.00
Tangible BV / Share (Annual)$0.72
Forward P/E34.92x
Price vs S&P 500 (52W)4.26%
P/E Ratio (TTM)9.02x
Year-to-Date Return21.03%
5-Day Price Return-4.55%
EPS Normalized (Annual)$1.21
ROA (5Y Avg)-17.37%
Net Profit Margin (Annual)30.16%
Month-to-Date Return-0.84%
Cash Flow / Share (TTM)$-1.24
EBITD / Share (Annual)$1.54
Operating Margin (Annual)37.00%
LT Debt / Equity (Annual)1.08x
P/CF (TTM)6.85x
ROI (5Y Avg)-77.15%
P/E Excl Extra (TTM)9.02x
LT Debt / Equity (Quarterly)0.80x
EPS Basic Excl Extra (TTM)$1.20
P/TBV (Quarterly)4.30x
P/B Ratio (Annual)13.88x
Inventory Turnover (TTM)2.83x
Pretax Margin (TTM)30.56%
Book Value / Share (Annual)$0.25
Price vs S&P 500 (13W)32.46%
Beta0.66x
P/FCF (Annual)6.90x
Revenue / Share (TTM)$3.99
ROE (TTM)-328.82%
52-Week Low$6.00
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.20
4.27
4.25
4.25
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
BCRXBioCryst Pharmaceuticals Inc | 2.72x | 94.10% | 97.82% | — | $9.52 |
AMGNAmgen Inc | 5.13x | 9.95% | 73.30% | 2.93% | $349.39 |
GILDGilead Sciences Inc | 5.84x | 2.40% | 78.83% | 133.64% | $138.55 |
ARGXargenx SE American Depositary Shares | 12.46x | 89.56% | 150.91% | — | $828.35 |
BNTXBioNTech SE American Depositary Share | 8.75x | -11.81% | 84.21% | — | $102.12 |
BIIBBiogen Inc. Common Stock | 2.60x | 2.22% | 75.69% | -18.77% | $176.02 |
MRNAModerna, Inc. Common Stock | 11.02x | -39.93% | 70.32% | — | $54.68 |
NBIXNeurocrine Biosciences Inc | 4.49x | 21.45% | 98.18% | 2.31% | $128.41 |
EXELExelixis Inc | 4.96x | 6.85% | 96.39% | 31.10% | $44.38 |
TECHBio-Techne Corp. | 7.60x | 1.64% | 66.60% | -20.58% | $57.36 |
HALOHalozyme Therapeutics, Inc. | 5.74x | 37.55% | 83.62% | 22.89% | $66.64 |
About
BioCryst Pharmaceuticals is a biotechnology company developing small-molecule drugs that target key enzymes involved in infectious and inflammatory diseases. The company's clinical and preclinical pipeline addresses acute and seasonal influenza, hereditary angioedema, filoviruses including Ebola and Marburg, and oncology. BioCryst leverages computational biology and medicinal chemistry to advance its targeted therapeutic candidates.